Skip to main content

Articles

Page 1 of 2

  1. Iron deficiency (ID) and anemia are common in both heart failure (HF) and cancer patients and are associated with poor quality of life and survival. The aims of this study were (1) to evaluate the prevalence, ...

    Authors: E. Čiburienė, J. Čelutkienė, S. Aidietienė, G. Ščerbickaitė and A. R. Lyon

    Citation: Cardio-Oncology 2020 6:29

    Content type: Research

    Published on:

  2. Re-allocation of resources during the COVID-19 pandemic has resulted in delays in care delivery to patients with cardiovascular disease and cancer. The ability of health care providers to provide optimal care ...

    Authors: Diego Sadler, Jeanne M. DeCara, Joerg Herrmann, Anita Arnold, Arjun K. Ghosh, Husam Abdel-Qadir, Eric H. Yang, Sebastian Szmit, Nausheen Akhter, Monika Leja, Carolina Maria Pinto Domingues Carvalho Silva, Jayant Raikhelkar, Sherry-Ann Brown, Susan Dent, Rupal O’Quinn, Franck Thuny…

    Citation: Cardio-Oncology 2020 6:28

    Content type: Research

    Published on:

  3. Breast cancer survivors have double the risk of mortality from cardiovascular disease than age-matched women without a cancer history. Reynolds risk score (RRS) is a validated algorithm for the assessment of c...

    Authors: Kyuwan Lee, Nathalie Sami, Debu Tripathy, Wendy Demark-Wahnefried, Mary K. Norris, Kerry S. Courneya and Christina M. Dieli-Conwright

    Citation: Cardio-Oncology 2020 6:27

    Content type: Short communication

    Published on:

  4. Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth...

    Authors: Sagar Sardesai, Jasmine Sukumar, Mahmoud Kassem, Marilly Palettas, Julie Stephens, Evan Morgan, Daniel Addison, Ragavendra Baliga, Daniel G. Stover, Jeffrey VanDeusen, Nicole Williams, Mathew Cherian, Maryam Lustberg, Robert Wesolowski and Bhuvaneswari Ramaswamy

    Citation: Cardio-Oncology 2020 6:26

    Content type: Research

    Published on:

  5. Sacubitril/Valsartan (S/V) is a novel and remarkably effective opportunity to treat heart failure with reduced ejection fraction (HFrEF). However, patients with HFrEF induced by cancer therapy were a priori ex...

    Authors: Massimiliano Camilli, Marco Giuseppe Del Buono, Pierantonio Menna and Giorgio Minotti

    Citation: Cardio-Oncology 2020 6:25

    Content type: Short communication

    Published on:

    The original article was published in Cardio-Oncology 2020 6:24

  6. Cancer therapy-related cardiac dysfunction (CTRCD) is a critical problem with an impact on both oncological and cardiovascular prognosis, especially when it prevents patients from receiving cancer treatment. S...

    Authors: Vanesa Gregorietti, Teresa Lopez Fernandez, Diego Costa, Elías Ortega Chahla and Andrés J. Daniele

    Citation: Cardio-Oncology 2020 6:24

    Content type: Research

    Published on:

    The Short communication to this article has been published in Cardio-Oncology 2020 6:25

  7. Anthracycline-induced cardiac dysfunction (ACD) is a notorious side effect of anticancer treatment. It has been described as a phenomenon of a continuous progressive decline of cardiac function, eventually lea...

    Authors: Janine A. M. Kamphuis, Marijke Linschoten, Maarten J. Cramer, Pieter A. Doevendans, Folkert W. Asselbergs and Arco J. Teske

    Citation: Cardio-Oncology 2020 6:23

    Content type: Research

    Published on:

  9. Immune checkpoint inhibition is part of standard systemic management for many advanced malignancies. Toxicities from this treatment approach are unpredictable, though usually reversible with management per est...

    Authors: Puja Arora, Laura Talamo, Patrick Dillon, Ryan D. Gentzler, Trish Millard, Michael Salerno, Craig L. Slingluff Jr and Elizabeth M. Gaughan

    Citation: Cardio-Oncology 2020 6:21

    Content type: Research

    Published on:

  10. An innovative Cardio-Oncology meeting was held in Houston, Texas in January of 2020. This gathering was intended to broaden the scope of Cardio-Oncology to include major presentations by clinicians and researc...

    Authors: Anecita P. Fadol, Nicolas L. Palaskas, Michael S. Ewer and Anita Deswal

    Citation: Cardio-Oncology 2020 6:20

    Content type: Review

    Published on:

  11. Consideration of heart health for cancer survivors is increasingly important, as improved cancer survivorship has resulted in a growing number of survivors affected by cardiovascular disease. However, there is...

    Authors: Claire C. Conley, Neha G. Goyal and Sherry-Ann Brown

    Citation: Cardio-Oncology 2020 6:19

    Content type: Short communication

    Published on:

  12. Coronary emboli from malignant tumors rarely cause acute myocardial infarction. We report the case of a patient with tumor embolism from an upper tract urothelial carcinoma that caused acute myocardial infarct...

    Authors: Taku Yasui, Yohei Okuda, Wataru Shioyama, Toru Oka, Tatsuya Nishikawa, Risa Kamada, Koji Hatano, Kazuo Nishimura and Masashi Fujita

    Citation: Cardio-Oncology 2020 6:18

    Content type: Short communication

    Published on:

  13. Proteasome inhibitors such as carfilzomib are indicated in multiple myeloma patients showing relapse and/or refractoriness of clonal activity. However, this therapy has been associated with a significant incid...

    Authors: Arnold Méndez-Toro, Cándida Díaz-Brochero and Estivalis Acosta-Gutiérrez

    Citation: Cardio-Oncology 2020 6:17

    Content type: Short communication

    Published on:

  14. In cardio-oncology, a range of clinical dilemmas can be identified where high-quality evidence for management is still lacking. The aim of this project was to study clinical practices and expert approaches to ...

    Authors: E. Hedayati, A. Papakonstantinou, A. Månsson-Broberg, J. Bergh, L. Hubbert and R. Altena

    Citation: Cardio-Oncology 2020 6:16

    Content type: Research

    Published on:

  15. Hypertension impacts overall prognosis in cancer patients. There are no specific recommendations for its management in these patients. We report a case series of 5 cancer patients with suboptimal BP lowering a...

    Authors: Mishita Goel, Rajiv Sunil Varandani and Tochukwu M. Okwuosa

    Citation: Cardio-Oncology 2020 6:15

    Content type: Short communication

    Published on:

  16. Various breast cancer (BC) treatments, such as chemotherapy and targeted therapies, increase cardiotoxicity-risk and lead to premature ischemic heart disease and heart failure among survivors. Reducing this ad...

    Authors: Yvonne Koop, Saloua El Messaoudi, Hester Vermeulen, Angela H. E. M. Maas and Femke Atsma

    Citation: Cardio-Oncology 2020 6:14

    Content type: Research

    Published on:

  17. Adverse cardiac remodeling is an important precursor to anthracycline-related cardiac dysfunction, however conventional remodeling indices are limited. We sought to examine the utility of statistical atlas-der...

    Authors: Hari K. Narayan, Ronghui Xu, Nickolas Forsch, Sachin Govil, David Iukuridze, Lanie Lindenfeld, Eric Adler, Sanjeet Hegde, Adriana Tremoulet, Bonnie Ky, Saro Armenian, Jeffrey Omens and Andrew D. McCulloch

    Citation: Cardio-Oncology 2020 6:13

    Content type: Research

    Published on:

  18. Radiation-induced coronary artery disease (R-CAD) has become an increasingly recognized phenomenon. Although the clinical relationship between radiation therapy and CAD risk is well known, there is minimal inv...

    Authors: Yaser Khalid, Michael Fradley, Neethi Dasu, Kirti Dasu, Ankit Shah and Adam Levine

    Citation: Cardio-Oncology 2020 6:12

    Content type: Research

    Published on:

  20. Doxorubicin remains one of the most common causes of cardiotoxicity in patients with lymphoma, leading to significant morbidity and mortality. Early decline in left ventricular (LV) ejection fraction predicts ...

    Authors: Maria Isabel Camara Planek, Ahmad Manshad, Kyaw Hein, Mohamad Hemu, Fatima Ballout, Rajiv Varandani, Parameswaran Venugopal and Tochukwu Okwuosa

    Citation: Cardio-Oncology 2020 6:10

    Content type: Research

    Published on:

  21. Cardio-Oncology (CO) is a new subspecialty that thrives mostly in large academic quaternary centers. This study describes how to establish a successful cardio-oncology program, with limited resources, in order...

    Authors: Diego Sadler, Chakra Chaulagain, Beatrice Alvarado, Robert Cubeddu, Elizabeth Stone, Thomas Samuel, Bruno Bastos, David Grossman, Chieh-Lin Fu, Evan Alley, Arun Nagarajan, Timmy Nguyen, Wesam Ahmed, Leah Elson and Zeina Nahleh

    Citation: Cardio-Oncology 2020 6:9

    Content type: Research

    Published on:

  22. Cancer survivors with prior chest radiation therapy (C-XRT) frequently present with aortic stenosis (AS) as the first manifestation of radiation-induced heart disease. They are considered high-risk for surgica...

    Authors: Meer Rabeel Zafar, Syed Farrukh Mustafa, Timothy W. Miller, Talal Alkhawlani and Umesh C. Sharma

    Citation: Cardio-Oncology 2020 6:8

    Content type: Research

    Published on:

  23. Contrasting to the well documented tyrosine kinase inhibitor (TKI)-induced hypertension, little is known on their intrinsic vasomotor effects. We investigated the vasomotor effects of sorafenib, a widely used ...

    Authors: Hubert Dabiré, Fatou Dramé, Nelly Cita and Bijan Ghaleh

    Citation: Cardio-Oncology 2020 6:7

    Content type: Research

    Published on:

  24. Radiotherapy has been associated with late dose-dependent cardiovascular toxicity. In this cross-sectional pilot study, radiation dose distributions were correlated with areas of localized and diffuse myocardi...

    Authors: Anthony Ricco, Alexander Slade, Justin M. Canada, John Grizzard, Franklin Dana, Leila Rezai Gharai, Keith Neiderer, Armando Vera, Antonio Abbate and Elisabeth Weiss

    Citation: Cardio-Oncology 2020 6:6

    Content type: Research

    Published on:

  25. Anthracyclines are a mainstay of chemotherapy. However, a relatively frequent adverse outcome of anthracycline treatment is cardiomyopathy. Multiple genetic studies have begun to dissect the complex genetics u...

    Authors: Timothy N. McOwan, Lauren A. Craig, Anne Tripdayonis, Kathy Karavendzas, Michael M. Cheung, Enzo R. Porrello, Rachel Conyers and David A. Elliott

    Citation: Cardio-Oncology 2020 6:5

    Content type: Research

    Published on:

  26. High dose melphalan is commonly used as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. There are reports of adverse cardiac events with melphalan manifested by supraventri...

    Authors: Liang-Liang Ma, Ying Liu, Si-Xun Jia, Hai-Chen Lv, Mei-Yun Fang and Yun-Long Xia

    Citation: Cardio-Oncology 2020 6:4

    Content type: Short communication

    Published on:

  27. Irradiation of the heart during cancer radiotherapy is associated with a dose-dependent risk of heart failure. Animal studies have demonstrated that irradiation leads to an inflammatory response within the hea...

    Authors: Justin M. Canada, Georgia K. Thomas, Cory R. Trankle, Salvatore Carbone, Hayley Billingsley, Benjamin W. Van Tassell, Ronald K. Evans, Ryan Garten, Elisabeth Weiss and Antonio Abbate

    Citation: Cardio-Oncology 2020 6:2

    Content type: Short communication

    Published on:

  28. Our recent study has revealed that many hospitalized patients with acquired long QT syndrome (ALQTS) are cancer patients. This study aims to determine the risk factors and outcomes of hospitalized cancer patie...

    Authors: Yajuan Lin, Haixu Yu, Fei Liu, Cheng Chen, Yanli Zhang, Binhao Wang, Yiheng Yang, Ying Liu, Li Zhang and Yunlong Xia

    Citation: Cardio-Oncology 2020 6:3

    Content type: Research

    Published on:

  29. Continuous infusion of doxorubicin or dexrazoxane pre-treatment prior to bolus doxorubicin are proven strategies to protect against doxorubicin-induced cardiotoxicity. Recently, global longitudinal peak systol...

    Authors: Jieli Li, Hui-Ming Chang, Jose Banchs, Dejka M. Araujo, Saamir A. Hassan, Elizabeth A. Wagar, Edward T. H. Yeh and Qing H. Meng

    Citation: Cardio-Oncology 2020 6:1

    Content type: Research

    Published on:

  30. The lack of a validated symptom assessment instrument in Spanish for patients with cancer and heart failure (HF) can affect the care and impede the recruitment and participation of Spanish-speaking patients in...

    Authors: Anecita Fadol, Joaquin Buitrago, Maria C. Diaz, Valerie Shelton, Carolyn Harty and Tito R. Mendoza

    Citation: Cardio-Oncology 2019 5:19

    Content type: Research

    Published on:

  31. Cancer diagnostics and therapies have improved steadily over the last few decades, markedly increasing life expectancy for patients at all ages. However, conventional and newer anti-neoplastic therapies can ca...

    Authors: Neha Bansal, M. Jacob Adams, Sarju Ganatra, Steven D. Colan, Sanjeev Aggarwal, Rudolf Steiner, Shahnawaz Amdani, Emma R. Lipshultz and Steven E. Lipshultz

    Citation: Cardio-Oncology 2019 5:18

    Content type: Review

    Published on:

  32. Takotsubo syndrome (TTS), primarily an acute myocardial inflammatory condition engendered by catecholamine exposure, is associated with similar long-term mortality rates to those of patients with acute myocard...

    Authors: Thanh H. Nguyen, Jeanette Stansborough, Gao J. Ong, Sven Surikow, Timothy J. Price and John D. Horowitz

    Citation: Cardio-Oncology 2019 5:20

    Content type: Research

    Published on:

  33. Assessment of cardiac function after treatment for breast cancer relies on interval evaluation of ventricular function through echocardiography. Women who undergo mastectomy more frequently choose to undergo b...

    Authors: Joaquin Duarte Ow, Mohamad Hemu, Anel Yakupovich, Parva Bhatt, Hannah Gaddam, Nicole Prabhu, Ibtihaj Fughhi, Melody Cobleigh, Melissa Tracy, Louis Fogg and Tochukwu Okwuosa

    Citation: Cardio-Oncology 2019 5:17

    Content type: Research

    Published on:

  34. Dexrazoxane protects from lower-cumulative-dose doxorubicin cardiotoxicity, but the effect of dexrazoxane in children with sarcoma treated with higher-cumulative-dose doxorubicin is unknown.

    Authors: Lisa M. Kopp, Richard B. Womer, Cindy L. Schwartz, David H. Ebb, Vivian I. Franco, David Hall, Donald A. Barkauskas, Mark D. Krailo, Holcombe E. Grier, Paul A. Meyers, Leonard H. Wexler, Neyssa M. Marina, Katherine A. Janeway, Richard Gorlick, Mark L. Bernstein and Steven E. Lipshultz

    Citation: Cardio-Oncology 2019 5:15

    Content type: Research

    Published on:

  35. To enhance the understanding of cardiovascular care delivery in childhood cancer patients and survivors.

    Authors: Thomas D. Ryan, William L. Border, Carissa Baker-Smith, Ana Barac, Matthew J. Bock, Mary M. Canobbio, Nadine F. Choueiter, Devyani Chowdhury, Katheryn E. Gambetta, Julie S. Glickstein, Lavanya Kondapalli, Seema Mital, Vasum Peiris, Russell J. Schiff, Robert L. Spicer, Jeffrey A. Towbin…

    Citation: Cardio-Oncology 2019 5:16

    Content type: Research

    Published on:

  36. 5-Fluorouracil (5-FU) is an antimetabolite chemotherapy used for a variety of solid tumors. It has the potential to cause a wide spectrum of cardiotoxicity, ranging from asymptomatic electrocardiographic chang...

    Authors: Cai Yuan, Hiral Parekh, Carmen Allegra, Thomas J. George and Jason S. Starr

    Citation: Cardio-Oncology 2019 5:13

    Content type: Review

    Published on:

  37. Cardio-oncology is a young sub-specialty that addresses the needs of cancer patients at risk of, or who have experienced cancer therapy related cardiac dysfunction (CTRCD). This study assessed clinicians’ unde...

    Authors: J. Peng, M. Rushton, C. Johnson, C. Brezden-Masley, J. Sulpher, Miliyun G. Chiu, I. D. Graham and S. Dent

    Citation: Cardio-Oncology 2019 5:12

    Content type: Research

    Published on:

  38. Cardiotoxicity is a potential complication of anticancer therapy. While guidelines have been developed to assist practitioners, an effective, evidence based clinical pathway for the treatment of cardiotoxicity...

    Authors: Robyn A. Clark, Tania S. Marin, Alexandra L. McCarthy, Julie Bradley, Suchi Grover, Robyn Peters, Christos S. Karapetis, John J. Atherton and Bogda Koczwara

    Citation: Cardio-Oncology 2019 5:14

    Content type: Research

    Published on:

  39. Cardiovascular disease (CVD) is the leading non-malignant cause of death in childhood cancer survivors. Heightened risk of CVD is often attributable to treatment with anthracycline chemotherapy. Anthracycline-...

    Authors: Treya M. Long, Channa E. Marsh, Lawrence G. Dembo, Philip Watson, Karen E. Wallman, Thomas S. Walwyn, Catherine S. Choong and Louise H. Naylor

    Citation: Cardio-Oncology 2019 5:11

    Content type: Research

    Published on:

  40. Early recognition of anthracycline-induced cardiomyopathy may reduce morbidity and mortality in children, but risk stratification tools are lacking. This study evaluates whether electrocardiogram (ECG) changes...

    Authors: Lajja Desai, Lauren Balmert, Jennifer Reichek, Amanda Hauck, Katheryn Gambetta and Gregory Webster

    Citation: Cardio-Oncology 2019 5:10

    Content type: Research

    Published on:

  41. Improved cancer survival in patients treated with thoracic ionizing radiation (XRT) has resulted in unanticipated surge of aortic stenosis. Transcatheter aortic valve replacement (TAVR) has revolutionized the ...

    Authors: Nikhil Agrawal, Sharma Kattel, Sameer Waheed, Ankita Kapoor, Vasvi Singh, Ashutosh Sharma, Brian J. Page, Kristopher M. Attwood, Vijay Iyer, Saraswati Pokharel and Umesh C. Sharma

    Citation: Cardio-Oncology 2019 5:8

    Content type: Research

    Published on:

  42. Cardiotoxicity is an adverse effect of trastuzumab (TRA) in the treatment of human epidermal growth factor 2 positive (HER2+) breast cancer. Current literature on the cardioprotective effects of agents targete...

    Authors: Melissa Y. Y. Moey, Darla K. Liles and Blase A. Carabello

    Citation: Cardio-Oncology 2019 5:9

    Content type: Research

    Published on:

  43. Cancer is a chronic condition that induces significant emotional and physical stress, which may increase the risk for developing Takotsubo cardiomyopathy (TCM).

    Authors: Aakash Desai, Arish Noor, Saurabh Joshi and Agnes S. Kim

    Citation: Cardio-Oncology 2019 5:7

    Content type: Review

    Published on:

  44. The management of patients with cancer and concurrent heart failure (HF) is challenging. The increased complexity of treatment and the occurrence of multiple overlapping symptoms may lead to frequent hospital ...

    Authors: Anecita Fadol, Joylynmae Estrella, Valerie Shelton, Maryam Zaghian, Diane Vanbenschop, Valerie Counts, Tito R. Mendoza, David Rubio and Patricia A. Johnston

    Citation: Cardio-Oncology 2019 5:5

    Content type: Short communication

    Published on:

  46. Early identification of cardiac dysfunction by non-invasive imaging in HER2-positive breast cancer patients treated with trastuzumab is challenging. In particular multigated acquisition (MUGA) scan, which is m...

    Authors: Nathalie I. Bouwer, Crista Liesting, Marcel J. M. Kofflard, Sylvia M. Sprangers-van Campen, Jasper J. Brugts, Jos J. E. M. Kitzen, Michael A. Fouraux, Mark-David Levin and Eric Boersma

    Citation: Cardio-Oncology 2019 5:4

    Content type: Research

    Published on:

  47. Cancer survivors experience on average a 20% reduction in peak exercise capacity (VO2 peak) post-cancer treatment. Intermuscular fat (IMF) is a strong predictor of reduced exercise capacity in heart failure (HF) ...

    Authors: Kerryn W. Reding, Peter Brubaker, Ralph D’Agostino Jr, Dalane W. Kitzman, Barbara Nicklas, Dale Langford, Michael Grodesky and W. Gregory Hundley

    Citation: Cardio-Oncology 2019 5:3

    Content type: Short communication

    Published on:

  48. Anthracycline chemotherapy is an effective and widely used treatment for solid tumors and hematological malignancies regardless of its known cardiotoxicity. The mechanisms of the cardiotoxicity are not fully u...

    Authors: Amanda J. Favreau-Lessard, Hagen Blaszyk, Michael A. Jones, Douglas B. Sawyer and Ilka M. Pinz

    Citation: Cardio-Oncology 2019 5:2

    Content type: Research

    Published on:

  49. Cardiotoxicity associated with anthracycline-based chemotherapies has limited their use in patients with preexisting cardiomyopathy or heart failure. Dexrazoxane protects against the cardiotoxic effects of ant...

    Authors: Sarju Ganatra, Anju Nohria, Sachin Shah, John D. Groarke, Ajay Sharma, David Venesy, Richard Patten, Krishna Gunturu, Corrine Zarwan, Tomas G. Neilan, Ana Barac, Salim S. Hayek, Sourbha Dani, Shantanu Solanki, Syed Saad Mahmood and Steven E. Lipshultz

    Citation: Cardio-Oncology 2019 5:1

    Content type: Research

    Published on:

  50. Emerging evidence suggests potential arterial damage with the use of anthracycline-based chemotherapeutic regimens. We determined arterial function at rest and during exercise in anthracycline-treated adult su...

    Authors: Vivian Wing-yi Li, Anthony Pak-yin Liu, Karin Kar-Huen Ho, Jeffrey Ping-Wa Yau, Daniel Ka-leung Cheuk and Yiu-fai Cheung

    Citation: Cardio-Oncology 2018 4:9

    Content type: Research

    Published on:

Submit manuscript

Follow

Annual Journal Metrics

  • Speed
    36 days to first decision for reviewed manuscripts only
    36 days to first decision for all manuscripts
    87 days from submission to acceptance
    30 days from acceptance to publication

    Usage 
    61,438 Downloads
    214 Altmetric Mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Cardio-Oncology

ISSN: 2057-3804

Contact us